Page last updated: 2024-09-04

1,3,5-triaza-7-phosphaadamantane and Multiple Myeloma

1,3,5-triaza-7-phosphaadamantane has been researched along with Multiple Myeloma in 1 studies

*Multiple Myeloma: A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. [MeSH]

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Badillo Patzmay, GV; Kwiecień, A; Lupidi, G; Nabissi, M; Pettinari, C; Pettinari, R; Santoni, G; Smoleński, P; Wołoszyn, A1

Other Studies

1 other study(ies) available for 1,3,5-triaza-7-phosphaadamantane and Multiple Myeloma

ArticleYear
Ru(ii)-(PTA) and -mPTA complexes with N
    Dalton transactions (Cambridge, England : 2003), 2017, Aug-14, Volume: 46, Issue:30

    Topics: 2,2'-Dipyridyl; Adamantane; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Coordination Complexes; Crystallography, X-Ray; Humans; Multiple Myeloma; Nitrogen; Organophosphorus Compounds; Phenanthrolines; Ruthenium

2017